Drug ID:Drug74
Drug Name:ORE1001
CID:448281
DrugBank ID:DB12271
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT01039597
Molecular Formula:C19H23Cl2N3O4
Molecular Weight:428.3 g/mol
Isomeric SMILES:CC(C)C[C@@H](C(=O)O)N[C@@H](CC1=CN=CN1CC2=CC(=CC(=C2)Cl)Cl)C(=O)O
Synonyms:MLN-4760; 305335-31-3; MLN4760; GL-1001; ORE-1001; GL1001; ORE1001; ORE-1001 FREE ACID; 4LD0ZHV25K; (2S)-2-[[(2S)-3-[3-[(3,5-dichlorophenyl)methyl]imidazol-4-yl]-1-hydroxy-1-oxopropan-2-yl]amino]-4-methylpentanoic acid
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt626 448281 Mln-4760 7124 TNF Rattus norvegicus (Norway rat) 27302421 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [lipopolysaccharides results in i
dt627 448281 Mln-4760 7431 VIM Mus musculus (house mouse) 33007385 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid promotes the reaction [silicon dioxide results in increased expression of VIM protein]|2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylp
dt628 448281 Mln-4760 1636 ACE Homo sapiens (human) 26851370 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid results in decreased activity of ACE protein
dt629 448281 Mln-4760 1636 ACE Mus musculus (house mouse) 33007385 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [angiotensin I (1-7) inhibits the reaction [AGT protein results in increased expression of ACE mrna]]|2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3
dt630 448281 Mln-4760 183 AGT Mus musculus (house mouse) 33007385 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [angiotensin I (1-7) inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]|2-(1-carboxy-2-(3-(3,5-dichlor
dt631 448281 Mln-4760 183 AGT Mus musculus (house mouse) 29969931 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]
dt632 448281 Mln-4760 183 AGT Rattus norvegicus (Norway rat) 27302421 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [lipopolysaccharides results in increased expression of AGT protein]]|2-(1-carboxy-2-(3-(3,5-dichlorobenzy
dt633 448281 Mln-4760 3553 IL1B Rattus norvegicus (Norway rat) 27302421 SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [lipopolysaccharides results in increased expression of IL1B protein]]]|2
dt634 448281 Mln-4760 3569 IL6 Rattus norvegicus (Norway rat) 27302421 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [lipopolysaccharides results in increased expression of IL6 protein]]
dt635 448281 Mln-4760 5594 MAPK1 Rattus norvegicus (Norway rat) 27302421 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT01039597 Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis PHASE1|PHASE2 UNKNOWN Ore Pharmaceuticals, Inc. Mild to Moderate Ulcerative Colitis DRUG: ORE1001|DRUG: Placebo Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

No related literature

You can run management commands to establish drug-literature associations